Navigation Links
Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
Date:6/12/2008

Reports Full Assessment of Data from Positive Phase 2a Trial

WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that based on feedback from the Food and Drug Administration, the Company plans to initiate a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar disorder later this year. This will be a multi-center, parallel arm placebo-controlled, clinical trial in which approximately 150 patients with bipolar disorder will receive either RG2417 or a placebo twice a day for eight-weeks. This study is designed to assess the efficacy and safety of RG2417 on the symptom of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Gary S. Sachs, M.D., founder and director of the Bipolar Clinic and Research Program at the Massachusetts General Hospital and an Associate Professor of Psychiatry at the Harvard Medical School will be the Principal Investigator of this study.

Repligen previously reported positive initial results from a Phase 2a clinical trial of RG2417 in patients with bipolar disorder. We have now completed our assessment of the data and have found that patients with a history of more frequent symptoms demonstrated greater improvements when treated with RG2417 than patients without a history of frequent symptoms. For example, patients with more than 5 episodes of depression over their entire life (n=50) demonstrated greater improvements in their symptoms of depression compared to patients with 5 or fewer lifetime episodes of depression. From weeks 2-6 of treatment, the patients with more than 5 lifetime episodes of depression who received RG2417 had an average improvement on MADRS of 5.5 points over place
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. ... pivotal TELESTAR Phase 3 clinical trial met its ... etiprate in treating cancer patients with carcinoid syndrome ... standard of care. Telotristat etiprate was discovered using ... and is the company,s first discovery to complete ...
(Date:7/31/2015)... , July 31, 2015  Physicians and payers ... the biopharmaceutical market. Patients are better informed and ... and switching therapies. This shift in power is ... efforts toward patient-focused marketing. As part ... have learned it,s important to educate, communicate and ...
(Date:7/31/2015)... 2015  In today,s ever-changing marketplace, call centers must ... increasingly connected, and increasingly impatient with slow service. The ... channels and tools is driving call centers to explore ... According to research by benchmarking firm, Best Practices, ... in a call center study realize the impact of ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
... 20, 2011 Reportlinker.com announces that a ... its catalogue: Orthopaedics: Market ... http://www.reportlinker.com/p0573671/Orthopaedics-Market-Prospects-GlobalCompetition .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine ... is projected to be 5% over the ...
... 19, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... its subsidiary, Valeant International (Barbados) SRL ("VIB"), has entered ... the Canadian marketing and distribution rights to Zuacta™, a ... used in conjunction with oral COX-2 inhibitors or NSAIDs ...
Cached Medicine Technology:Orthopaedics: Market Prospects & Global Competition 2Orthopaedics: Market Prospects & Global Competition 3Orthopaedics: Market Prospects & Global Competition 4Orthopaedics: Market Prospects & Global Competition 5Orthopaedics: Market Prospects & Global Competition 6Orthopaedics: Market Prospects & Global Competition 7Orthopaedics: Market Prospects & Global Competition 8Orthopaedics: Market Prospects & Global Competition 9Orthopaedics: Market Prospects & Global Competition 10Orthopaedics: Market Prospects & Global Competition 11Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada 2
(Date:8/2/2015)... ... 2015 , ... A new Phase I research study is looking at a ... by Kenneth G. Lucas, M.D. , chief of the division of pediatric hematology/oncology ... Kosair Children’s Hospital and in the UofL Department of Pediatrics . ...
(Date:8/2/2015)... ... , ... For many “would be” entrepreneurs, starting a new business can prove to be ... start a business.” Neither needs be a major obstacle. , The U.S. has always ... business and be successful. The risks of starting a business can be high but the ...
(Date:8/2/2015)... Orion, Clarkston, Metamora Michigan (PRWEB) , ... ... ... Pelvic Organ Prolapse (POP) results when the supportive muscles and connective tissues ... damaged. Causes of this weakness and damage include straining, heavy lifting, obesity, ...
(Date:8/2/2015)... ... , ... Molecular biologists in New South Wales say a protein linked to ... posted an article on the new research. Click here to read it now. ... in tissue samples from 42 patients with peritoneal mesothelioma and found a direct correlation ...
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office ... help the continuity of care for patients at this natural health care center in ... Clinic Director Mary Heal said. "Heather's role is vital to our approach because we ...
Breaking Medicine News(10 mins):Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:New Patient Advocate Enhances Natural Health Care 2
... Cell-Based ... Melanoma Therapy, BOTHELL, Wash., ... developer and marketer of,proprietary hypothermic storage and cryopreservation media products for,cells, ... products in the cellular therapy and cord blood banking,market segments., ...
... Michelle Reesman, RN, Executive,Director, Passport Health Colorado, says far ... adventurous types, leave,home without taking the basic steps she ... preparation into their health as they do into their,destination ... 1) Get advice from a travel health ...
... LENEXA, Kan., Mar. 26 Mediware Information,Systems (Nasdaq: ... systems for,blood and medication management, has announced its ... hospital,blood banks and LifeTrak(R) software for blood centers, ... standards being required in the,United States., With ...
... for Voters on Health Care and,Social Security, ... said the most recent Medicare trustees, report calls ... issues.,According to the program,s trustees, Medicare,s Hospital Insurance ... Medicare must,rely also on interest accrued on trust ...
... 26 Spheris, a leading global,outsource provider of clinical ... and twelve months ended December 31, 2007., Financial ... fourth quarter of 2007 were $48.6 million compared,with $51.4 ... million decrease,in net revenues during the fourth quarter of ...
... a company,developing breakthrough molecular imaging agents for ... it has entered into a licensing,agreement with ... and,commercialization of agents for diagnosis and treatment ... were co-developed by,FluoroPharma and MGH scientists, target ...
Cached Medicine News:Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 2Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 3Health News:The Top Ten Health Tips for International Travel 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 3Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 4Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 5Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 6Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 7Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 8Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 9Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 10Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 11Health News:FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD) 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: